Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo

Hypertension

Volumn 62, Issue 5, 2013, Pages 920-926

  Brouwers, Sofie ^a   Smolders, Ilse ^a   Massie, Ann ^a   Dupont, Alain G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

angiotensin II; blood pressure; compound 21; receptor angiotensin type 2; receptor, angiotensin type 1; renal circulation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOLDOPAM; ICATIBANT; INDOMETACIN; N(G) METHYLARGININE; NITRIC OXIDE; PROSTAGLANDIN; VASODILATOR AGENT; BRADYKININ; DOPAMINE RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; PYRIDINE DERIVATIVE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; HYPERTENSION; IN VIVO STUDY; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; KIDNEY; METABOLISM; PHYSIOLOGY; VASCULARIZATION; WISTAR KYOTO RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; BRADYKININ; CAPTOPRIL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FENOLDOPAM; IMIDAZOLES; INDOMETHACIN; KIDNEY; NITRIC OXIDE; OMEGA-N-METHYLARGININE; PYRIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; THIOPHENES; VASODILATION; VASODILATOR AGENTS;

EID: 84886432625     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.00762     Document Type: Article

References (34)

1. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
2. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension. 1997;30:1238-1246.
3. Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, Mezzano S, Ardiles L, Justo P, Ortiz A, Egido J. Renal expression of angiotensin type-2 receptors during kidney damage. Kidney Int. 2003;64(Suppl 86);S21-S26.
4. Hakam AC, Hussain T. Renal angiotensin II type-2 receptors are upregulated and mediate the candesartan-induced natriuresis/diuresis in obese Zucker rats. Hypertension. 2005;45:270-275.
5. Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension. 1998;32:467-472.
6. Ognibene DT, Oliveira PR, Marins de Carvalho LC, Costa CA, Espinoza LA, Criddle DN, Tano T, Soares de Moura R, Resende AC. Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors. Clin Exp Pharmacol Physiol. 2009;36:12-19.
7. Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension. 2000;35(1 Pt 2):155-163.
8. Cosentino F, Savoia C, De Paolis P, Francia P, Russo A, Maffei A, Venturelli V, Schiavoni M, Lembo G, Volpe M. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens. 2005;18(4 Pt 1):493-499.
9. Savoia C, Tabet F, Yao G, Schiffrin EL, Touyz RM. Negative regulation of Rho/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation. J Hypertens. 2005;23: 1037-1045.
10. Tofovic SP, Pong AS, Jackson EK. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension. 1991;18:774-782.
11. Carey RM. Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension. 2005;45:840-844.
12. Endo Y, Arima S, Yaoita H, Tsunoda K, Omata K, Ito S. Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats. J Vasc Res. 1998;35:421-427.
13. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab. 2008;19:84-87.
14. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE, Denton KM. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension. 2012;59:409-414.
15. Wan Y, Wallinder C, Plouffe B, et al. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem. 2004;47:5995-6008.
16. Li XC, Widdop RE. AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol. 2004;142: 821-830.
17. Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukaszuk A, Tourwé D, Chai SY, Albiston AL, Nahmias C, Walther T, Dupont AG. Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent. Hypertension. 2011;57:956-964.
18. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature. 1995;377:748-750.
19. Barber MN, Sampey DB, Widdop RE. AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. Hypertension. 1999;34:1112-1116.
20. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291-299.
21. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol. 2010;159:709-716.
22. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens. 2012;21:142-146.
23. Wang ZQ, Millatt LJ, Heiderstadt NT, Siragy HM, Johns RA, Carey RM. Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension. Hypertension. 1999;33:96-101.
24. Henrion D. Why do we need a selective angiotensin II type 2 receptor agonist? Hypertension. 2012;60:616-617.
25. You D, Loufrani L, Baron C, Levy BI, Widdop RE, Henrion D. High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation. 2005;111:1006-1011.
26. Verdonk K, Durik M, Abd-Alla N, Batenburg WW, van den Bogaerdt AJ, van Veghel R, Roks AJ, Danser AH, van Esch JH. Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptorindependent mechanism. Hypertension. 2012;60:722-729.
27. Yang J, Chen C, Ren H, Han Y, He D, Zhou L, Hopfer U, Jose PA, Zeng C. Angiotensin II AT(2) receptor decreases AT(1) receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats. J Hypertens. 2012;30:1176-1184.
28. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension. 2002;40:516-520.
29. Savoia C, Touyz RM, Volpe M, Schiffrin EL. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension. 2007;49:341-346.
30. Pees C, Unger T, Gohlke P. Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats. Int J Biochem Cell Biol. 2003;35:963-972.
31. Savoia C, Ebrahimian T, He Y, Gratton JP, Schiffrin EL, Touyz RM. Angiotensin II/AT2 receptor-induced vasodilation in stroke-prone spontaneously hypertensive rats involves nitric oxide and cGMP-dependent protein kinase. J Hypertens. 2006;24:2417-2422.
32. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, Carey RM. Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension. 2009;53:338-343.
33. Padia SH, Carey RM. AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function. Pflugers Arch. 2013;465:99-110.
34. Matrougui K, Loufrani L, Heymes C, Lévy BI, Henrion D. Activation of AT(2) receptors by endogenous angiotensin II is involved in flowinduced dilation in rat resistance arteries. Hypertension. 1999;34(4 Pt 1):659-665.